EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation

Yuxuan Wu, Xingkai Wang, Xiaona Sun, Xin Gao, Siqi Zhang, Jieting Shen, Hao Tian, Xueyao Chen, Hongyi Huang, Shuo Jiang, Boyang Zhang, Yingzi Zhang und 8 weitere

Acta Pharmaceutica Sinica B · 2025-09 · 15 (9) · 4511-4542

DOI: 10.1016/j.apsb.2025.07.009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2025-09. Verfasst von Yuxuan Wu und 19 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Pek…. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 296 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Beijing Municipality, China Postdoctoral Science Foundation, China National Nuclear Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Bench-to-bedsideCancer-associated fibroblastsFibroblast activation proteinRadionuclide therapyRadiopharmaceuticalRadiotheranosticsSmall molecule inhibitorsTumor microenvironment

Autor:innen und Institutionen

  • State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
  • School of Printing and Packaging Engineering, Beijing Institute of Graphic Communication, Beijing 102600, China.
  • Department of Orthopaedics, the Second Affiliated Hospital of Soochow University, Suzhou 215031, China.
  • Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences & Research Unit of Peptide Science, Chinese Academy of Medical Sciences, 2019RU066, Lanzhou University, Lanzhou 73000…
  • Department of Nuclear Medicine and Positron Emission Tomography Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310058, China.
  • Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.

Förderung

  • Natural Science Foundation of Beijing Municipality
  • China Postdoctoral Science Foundation
  • China National Nuclear Corporation
  • Beijing Nova Program
  • Chinese Academy of Medical Sciences Initiative for Innovative Medicine
  • Chinese Academy of Medical Sciences
  • Second Affiliated Hospital of Soochow University
  • National Natural Science Foundation of China

Zitieren

APA

Wu, Y., Wang, X., Sun, X., Gao, X., Zhang, S., Shen, J., Tian, H., Chen, X., Huang, H., Jiang, S., Zhang, B., Zhang, Y., Lu, M., Zhang, H., Sun, Z., Liu, R., Zhang, H., Zhang, M. R., Hu, K., & Wang, R. (2025). Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation. Acta Pharmaceutica Sinica B, 15(9), 4511-4542. https://doi.org/10.1016/j.apsb.2025.07.009

Vancouver

Wu Y, Wang X, Sun X, Gao X, Zhang S, Shen J, et al. Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation. Acta Pharmaceutica Sinica B. 2025;15(9):4511-4542. doi:10.1016/j.apsb.2025.07.009

BibTeX
@article{Wu2025,
  author = {Wu, Yuxuan and Wang, Xingkai and Sun, Xiaona and Gao, Xin and Zhang, Siqi and Shen, Jieting and Tian, Hao and Chen, Xueyao and Huang, Hongyi and Jiang, Shuo and Zhang, Boyang and Zhang, Yingzi and Lu, Minzi and Zhang, Hailong and Sun, Zhicheng and Liu, Ruping and Zhang, Hong and Zhang, Ming-Rong and Hu, Kuan and Wang, Rui},
  title = {Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2025},
  volume = {15},
  number = {9},
  pages = {4511--4542},
  doi = {10.1016/j.apsb.2025.07.009}
}
Kostenlos starten →